Dow Arthritis Clinical Research Award

Summary: The fiscal year 2026 (FY26) Arthritis Research Program (ATRP) Clinical Research Award (CRA) supports clinical research that evaluates disease-specific factors and interventions. Research is intended to generate clinically useful evidence with potential to optimize patient outcomes and inform clinical care or policy. Research addressing any and all types of arthritis is encouraged.

Applications must address one of two FY26 ATRP CRA Focus Areas: Prevention and Early Diagnosis, or Treatment and Mitigation of Disease Progression/Burden.

Distinctive Features: The FY26 ATRP CRA offers funding for two research levels. It is the responsibility of the applicant to select the level that aligns with the scope of the proposed research.

• Research Level 1: Applications proposing clinical research or early-phase/pilot clinical trials, to include new or emerging research that is not ready for a full-scale randomized controlled clinical trial.

• Research Level 2: Applications proposing a full-scale clinical trial.

Applications should include a community collaborator (e.g., patient/care partner, community-based organization consultant) who will provide advice and consultation during study design and throughout study planning and implementation. The ATRP encourages a community collaborator for Research Level 1 applications and requires a community collaborator for Research Level 2 applications.

Preliminary and/or published data are required.